Monitoring without impact analysis is just a press review
Regulatory monitoring for a medical device manufacturer covers MDCG guidance, the implementing acts of the MDR and the IVDR, harmonised standards, notified body position papers, national competent authority publications and, depending on your markets, those of the FDA. It is all public, it is all free, and nobody has the time to read it all.
But reading is not enough. In an audit, the notified body looks neither at your list of sources nor at your pile of downloaded PDFs. It looks at what you concluded, and what you changed.
That part, the longest and the most technical, is what RADAR takes on.
Not "new guidance has been published". But "your PMS plan, section 3.2, must say this".
How it works
Mapping your documentation
At the start, we get to know your device and your document system: technical documentation, risk management, clinical evaluation, post-market surveillance, QMS procedures. We build the correspondence between the regulatory requirements and your documents.
Monitoring screened against your profile
Class, software, sterility, target markets, MDR or legacy status, notified body, audit dates. Only the publications that apply to you are kept, with the reason why they apply.
Impact analysis on your documents
For each applicable publication: the documents affected, the exact section, the change needed, and the proposed wording. The passage of the official text and the passage of your document are both quoted, so you can check in a few minutes.
You validate, you integrate
You receive a summary ready to file in your monitoring log. You approve the changes in your quality system, under your own document control. You remain in control of your file, and that is what makes it defensible in an audit.
What a summary looks like
An example based on a real text, Regulation (EU) 2023/607, which extended the transitional provisions of the MDR. The device and the document references are fictitious.
| Reference | Regulation (EU) 2023/607, amending Article 120 of Regulation (EU) 2017/745 |
|---|---|
| Source | EUR-Lex, direct link to the passage quoted |
| Applicability | Relevant to you. Class IIa device certified under Directive 93/42/EEC, still placed on the market. The new end dates of the transition period and their conditions apply to you. |
| Your documents affected | PLN-REG-02 MDR transition plan, section 2 "Timeline" PRO-QUA-07 Regulatory monitoring procedure, annex "Deadlines" |
| Proposed wording | PLN-REG-02, section 2:
The CE certificate issued under Directive 93/42/EEC remains valid until 31 December 2028 (MDR, Article 120, as amended by Regulation (EU) 2023/607). Evidence that the extension conditions are met: Annex A. |
| Action | Complete Annex A with dated evidence: MDR-compliant QMS in place by 26 May 2024, formal application lodged with the notified body by 26 May 2024, written agreement signed by 26 September 2024. |
| Criticality | High: one unmet condition takes the device out of the transitional regime |
| Status | To be validated by the manufacturer |
Every subscriber also has an online area: all monitoring, one summary per publication (what it says, who it concerns, its deadlines), filterable by market, authority or date, and the publications already screened for their device, with the rationale. The tool is available in English and in French. Sign in
Pricing
A fixed price per month, based on the scope of your device. No billing on time spent, no surprises.
Your monitoring, self-service
For the quality team that keeps its own monitoring log.
Free 30-day trial, no bank card required
- Unlimited devices, 3 users included
- European Union, United States, United Kingdom, Switzerland and the other markets we monitor
- Publications screened against your profile, with the rationale
- Monitoring log: one decision per publication
- Monitoring report in Word for your quality system
- Deadline alerts and weekly digest
- No commitment, or €1,620 excl. VAT per year
One device, one market
For the start-up or SME without a full-time regulatory affairs manager.
Set-up: €1,500 excl. VAT
- 1 device, or a whole range with the same profile
- Class I or IIa
- European Union or United States, your choice
- Impact analysis on your documents
- Proposed wording for the changes
- Subscriber area: all monitoring, with the screening done for you
- Summaries ready for your monitoring log
- Monthly overview and deadline schedule
One device, several markets
For devices sold outside Europe, software and higher risk classes.
Set-up: €2,000 excl. VAT
- 1 device, or a whole range with the same profile
- Up to 3 markets: EU, United States, United Kingdom, Switzerland, Brazil, Japan, Australia
- Any risk class
- Software and AI: IEC 62304, cybersecurity, AI Act
- Impact analysis and proposed wording
- Subscriber area: all monitoring, with the screening done for you
- Summaries ready for your monitoring log
- Monthly overview and deadline schedule
Several ranges or more than 3 markets
For manufacturers managing several product families or wide international distribution.
Set-up depending on the scope
- Several ranges with different profiles
- More than 3 markets
- A single monthly fee, scope defined together
- Same summary and analysis format
Same profile: same class, same markets, same standards. The same publications apply, so you do not pay twice for the same monitoring. Software or a class IIb or III device falls under the Multi-marchés plan, even on a single market.
Scientific literature monitoring option for your CERs and PERs
With RADAR Autonome, you can also follow new publications and the vigilance of your equivalent devices, for your clinical or performance evaluation and your post-market surveillance (PMS, PMCF).
AI screening has been validated on a reference set of real articles and notices. Nothing is hidden: every article and every notice remains displayed, and every decision is yours. The option does not replace the critical appraisal of the articles or the writing of the CER or PER. Specific Terms: RAD-CP-LIT.
Already have a regulatory team?
Your team does the monitoring. We take the publications that call for the most expertise, and we deliver the impact analysis on your real documents, one at a time.
Why not give monitoring to a junior?
It is often the first reflex. Here is what each option really brings.
| In-house junior RA/QA officer | RADAR | |
|---|---|---|
| Cost | A salary, plus recruitment and supervision | From €600 excl. VAT per month |
| Spotting the publications | Yes | Yes, screened against your profile |
| Saying which document changes, and how to write it | Rarely, for lack of audit experience | Yes, with the proposed wording |
| Continuity | Leave, departures, recruitment to start again | No recruitment, no handover |
| Software, AI, markets outside the EU | Needs time to build the skills | Covered depending on the plan |
If you already have a junior, RADAR does not replace them: it takes away the most thankless and riskiest part, so that they can focus on the rest.
We propose, you decide. Applicability is justified, the impact is located, the wording is ready, but it is your quality system that approves the change. That is the rule of document control, and it is what makes your monitoring log defensible in front of an auditor.
Start your free 30-day trial
RADAR Autonome, €150 excl. VAT per month after the trial, no bank card required and no commitment. The tool is available in English: use the FR / EN switch at the top of the page.
Start your free 30-day trial Talk to us about your deviceFrequently asked questions
Do you edit our documents directly?
No. We identify the document and the section concerned, and we deliver the proposed wording. You integrate it and approve it in your quality system, under your own change control. You remain in control of your documentation, which is also what the notified body expects.
Is regulatory monitoring mandatory?
The MDR requires the manufacturer to keep its system up to date with regulation and the state of the art, and ISO 13485 expects a documented process. In practice, the notified body asks for the monitoring log and looks mainly at the impact analysis and the actions that follow from it.
What is the set-up for?
To map your documentation once and for all: which documents cover which requirements. This initial work is what then makes it possible to locate an impact down to the section, every month, without rereading everything.
Do you use artificial intelligence?
Yes, as a tool, to find the relevant passages faster in the publications and in your documents. Every analysis is reviewed and validated by a consultant before it is delivered to you, and every statement cites its source. The processing of your documents is governed by contract before any exchange.
What about the confidentiality of our documents?
Your documents are used only for your analysis. A non-disclosure agreement is signed before any exchange, and the processing conditions are set out in the contract. If your internal policy requires it, we discuss it before starting.
What happens in a month when a major publication changes a lot?
The subscription covers monitoring and routine impact analysis. If a publication requires major rework, such as rewriting technical documentation, we tell you and send you a separate quote before starting the work.
Who carries out the analyses?
A medical device regulatory affairs consultant who does this work every day, not an automatic aggregator. Anything that is a matter of interpretation is flagged as such.
Do you also monitor the scientific literature for our CERs?
Yes, with the scientific literature monitoring option of RADAR Autonome, at €50 excl. VAT per month per monitored CER or PER. It covers PubMed, Europe PMC and vigilance on equivalent devices, with AI screening, alerts and an exportable log. The critical appraisal of the articles remains yours.
Why a 12-month commitment?
Because regulation does not move at the same pace every month. Some months are quiet, others bring several important publications at once. The annual commitment allows a fixed, low price, without billing the busy months on time spent. RADAR Autonome, where you do the analysis yourself, has no commitment.